-
Je něco špatně v tomto záznamu ?
Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors
S. Croce, A. Ducoulombier, A. Ribeiro, T. Lesluyes, JC. Noel, F. Amant, L. Guillou, E. Stoeckle, M. Devouassoux-Shisheboran, N. Penel, A. Floquet, L. Arnould, F. Guyon, F. Mishellany, C. Chakiba, T. Cuppens, M. Zikan, A. Leroux, E. Frouin, I....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 2000 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 2000-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Elsevier Open Access Journals
od 2000-01-01 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources
od 1988
- MeSH
- analýza přežití MeSH
- dospělí MeSH
- leiomyom diagnóza genetika patologie MeSH
- leiomyosarkom diagnóza genetika patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidské chromozomy, pár 13 genetika MeSH
- lidské chromozomy, pár 17 genetika MeSH
- lidské chromozomy, pár 5 genetika MeSH
- lokální recidiva nádoru MeSH
- nádor z hladké svalové tkáně diagnóza genetika patologie MeSH
- nádory dělohy diagnóza genetika patologie MeSH
- prognóza MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stanovení celkové genové exprese * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The diagnosis of a uterine smooth muscle lesion is, in the majority of cases, straightforward. However, in a small number of cases, the morphological criteria used in such lesions cannot differentiate with certainty a benign from a malignant lesion and a diagnosis of smooth muscle tumor with uncertain malignant potential (STUMP) is made. Uterine leiomyosarcomas are often easy to diagnose but it is difficult or even impossible to identify a prognostic factor at the moment of the diagnosis with the exception of the stage. We hypothesize, for uterine smooth muscle lesions, that there is a gradient of genomic complexity that correlates to outcome. We first tested this hypothesis on STUMP lesions in a previous study and demonstrated that this 'gray category' could be split according to genomic index into two groups. A benign group, with a low to moderate alteration rate without recurrence and a malignant group, with a highly rearranged profile akin to uterine leiomyosarcomas. Here, we analyzed a large series of 77 uterine smooth muscle lesions (from 76 patients) morphologically classified as 19 leiomyomas, 14 STUMP and 44 leiomyosarcomas with clinicopathological and genomic correlations. We confirmed that genomic index with a cut-off=10 is a predictor of recurrence (P<0.0001) and with a cut-off=35 is a marker for poor overall survival (P=0.035). For the tumors confined to the uterus, stage as a prognostic factor was not useful in survival prediction. At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index ≥10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). Based on these findings (and the feasibility of genomic profiling by array-comparative genomic hybridization), genomic index, 5p and 17p gains prognostic value could be evaluated in future prospective chemotherapy trials.
Argot Lab Lausanne Switzerland Institut Universitaire de Pathologie Lausanne Switzerland
Department of Biopathology Institut Bergonié Comprehensive Cancer Centre Bordeaux France
Department of Medical Oncology Institut Bergonié Comprehensive Cancer Centre Bordeaux France
Department of Pathology Centre Jean Perrin Comprehensive Cancer Centre Clermont Ferrand France
Department of Pathology Centre JF Leclerc Comprehensive Cancer Centre Dijon France
Department of Pathology Centre Oscar Lambret Comprehensive Cancer Centre Lille France
Department of Pathology Hôpital Universitaire Lyon Sud Pierre Benite France
Department of Pathology ICO Site Paul Papin Comprehensive Cancer Centre Angers France
Department of Pathology Institut Gustave Roussy Comprehensive Cancer Centre Villejuif France
Department of Pathology University Hospital Poitiers France
Department of Surgery Institut Bergonié Comprehensive Cancer Centre Bordeaux France
KU Leuven University of Leuven Department of Oncology Gynaecologic Oncology
Oncology Department Centre Oscar Lambret Comprehensive Cancer Centre Lille France
University Hospitals Leuven Department of Obstetrics and Gynaecology Leuven Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028622
- 003
- CZ-PrNML
- 005
- 20190823102315.0
- 007
- ta
- 008
- 190813s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/modpathol.2017.185 $2 doi
- 035 __
- $a (PubMed)29327710
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Croce, Sabrina $u Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France. Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France.
- 245 10
- $a Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors / $c S. Croce, A. Ducoulombier, A. Ribeiro, T. Lesluyes, JC. Noel, F. Amant, L. Guillou, E. Stoeckle, M. Devouassoux-Shisheboran, N. Penel, A. Floquet, L. Arnould, F. Guyon, F. Mishellany, C. Chakiba, T. Cuppens, M. Zikan, A. Leroux, E. Frouin, I. Farre, C. Genestie, I. Valo, G. MacGrogan, F. Chibon,
- 520 9_
- $a The diagnosis of a uterine smooth muscle lesion is, in the majority of cases, straightforward. However, in a small number of cases, the morphological criteria used in such lesions cannot differentiate with certainty a benign from a malignant lesion and a diagnosis of smooth muscle tumor with uncertain malignant potential (STUMP) is made. Uterine leiomyosarcomas are often easy to diagnose but it is difficult or even impossible to identify a prognostic factor at the moment of the diagnosis with the exception of the stage. We hypothesize, for uterine smooth muscle lesions, that there is a gradient of genomic complexity that correlates to outcome. We first tested this hypothesis on STUMP lesions in a previous study and demonstrated that this 'gray category' could be split according to genomic index into two groups. A benign group, with a low to moderate alteration rate without recurrence and a malignant group, with a highly rearranged profile akin to uterine leiomyosarcomas. Here, we analyzed a large series of 77 uterine smooth muscle lesions (from 76 patients) morphologically classified as 19 leiomyomas, 14 STUMP and 44 leiomyosarcomas with clinicopathological and genomic correlations. We confirmed that genomic index with a cut-off=10 is a predictor of recurrence (P<0.0001) and with a cut-off=35 is a marker for poor overall survival (P=0.035). For the tumors confined to the uterus, stage as a prognostic factor was not useful in survival prediction. At stage I, among the tumors reclassified as molecular leiomyosarcomas (ie, genomic index ≥10), the poor prognostic markers were: 5p gain (overall survival P=0.0008), genomic index at cut-off=35 (overall survival P=0.0193), 13p loss including RB1 (overall survival P=0.0096) and 17p gain including MYOCD gain (overall survival P=0.0425). Based on these findings (and the feasibility of genomic profiling by array-comparative genomic hybridization), genomic index, 5p and 17p gains prognostic value could be evaluated in future prospective chemotherapy trials.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a lidské chromozomy, pár 13 $x genetika $7 D002882
- 650 _2
- $a lidské chromozomy, pár 17 $x genetika $7 D002886
- 650 _2
- $a lidské chromozomy, pár 5 $x genetika $7 D002895
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a stanovení celkové genové exprese $7 D020869
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leiomyom $x diagnóza $x genetika $x patologie $7 D007889
- 650 _2
- $a leiomyosarkom $x diagnóza $x genetika $x patologie $7 D007890
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 12
- $a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nádor z hladké svalové tkáně $x diagnóza $x genetika $x patologie $7 D018235
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a nádory dělohy $x diagnóza $x genetika $x patologie $7 D014594
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ducoulombier, Agnès $u Oncology Department, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France. Oncology Department, Centre Antoine Lacassagne, Comprehensive Cancer Centre, Nice, France.
- 700 1_
- $a Ribeiro, Agnès $u Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Lesluyes, Tom $u Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France. University of Bordeaux, Bordeaux, France.
- 700 1_
- $a Noel, Jean-Christophe $u Department of Pathology, Clinic of Gynecopathology and Senology, Erasme University Hospital, Brussels, Belgium.
- 700 1_
- $a Amant, Frédéric $u KU Leuven - University of Leuven, Department of Oncology, Gynaecologic Oncology; University Hospitals Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium. Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands.
- 700 1_
- $a Guillou, Louis $u Argot-Lab, Lausanne, Switzerland. Institut Universitaire de Pathologie, Lausanne, Switzerland.
- 700 1_
- $a Stoeckle, Eberhard $u Department of Surgery, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Devouassoux-Shisheboran, Mojgan $u Department of Pathology, Hôpital Universitaire Lyon Sud, Pierre Benite, France.
- 700 1_
- $a Penel, Nicolas $u Oncology Department, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France.
- 700 1_
- $a Floquet, Anne $u Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Arnould, Laurent $u Department of Pathology, Centre JF Leclerc, Comprehensive Cancer Centre, Dijon, France.
- 700 1_
- $a Guyon, Frédéric $u Department of Surgery, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Mishellany, Florence $u Department of Pathology, Centre Jean Perrin, Comprehensive Cancer Centre, Clermont-Ferrand, France.
- 700 1_
- $a Chakiba, Camille $u Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Cuppens, Tine $u KU Leuven - University of Leuven, Department of Oncology, Gynaecologic Oncology; University Hospitals Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium.
- 700 1_
- $a Zikan, Michal $u Gynaecological Oncology Center, Department of Obstetrics and Gynaecology, Charles University in Prague - First Faculty of Medicine and General University Hospital, Prague, Czech Republic.
- 700 1_
- $a Leroux, Agnès $u Department of Pathology, Centre Alexis Vautrin, Comprehensive Cancer Centre, Vandoeuvre-les Nancy, France.
- 700 1_
- $a Frouin, Eric $u Department of Pathology, University Hospital, Poitiers, France.
- 700 1_
- $a Farre, Isabelle $u Department of Pathology, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France.
- 700 1_
- $a Genestie, Catherine $u Department of Pathology, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France.
- 700 1_
- $a Valo, Isabelle $u Department of Pathology, ICO Site Paul Papin, Comprehensive Cancer Centre, Angers, France.
- 700 1_
- $a MacGrogan, Gaëtan $u Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France.
- 700 1_
- $a Chibon, Frédéric $u Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France. Institut National de la Santé et de la Recherche Medicale (INSERM) U1218, Bordeaux, France.
- 773 0_
- $w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 31, č. 5 (2018), s. 816-828
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29327710 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190823102529 $b ABA008
- 999 __
- $a ok $b bmc $g 1433771 $s 1067082
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 31 $c 5 $d 816-828 $e 20180112 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
- LZP __
- $a Pubmed-20190813
